VP-16和VM-26与铂类联合化疗合并放射治疗小细胞肺癌的疗效比较  

VP 16 and VM 26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer

作　　者：曾平耀[1] 殷莉群[1] 罗百灵[1] 刘振洋[2] 全性江 

机构地区：[1]湖南医科大学附属湘雅医院放疗科 [2]湖南省肿瘤医院

出　　处：《湖南医科大学学报》1998年第6期587-589,共3页Bulletin of Hunan Medical University

摘　　要：分别用含ＶＰ－１６的ＣＥＰ和ＥＰ方案及含ＶＭ－２６的ＶＭ－２６＋ＤＤＰ和ＶＭ－２６＋Ｃａｒｂｏｐｌａｔｉｎ方案合并放射治疗小细胞肺癌患者共７４例，以比较二者的近、远期疗效和毒副作用。结果示：ＶＰ－１６组有效率为９０．７％，ＶＭ－２６组为９３．５５％；ＶＰ－１６组的两年存活率为４４．１９％，ＶＭ－２６组为４８．３９％；ＶＰ－１６组的脑转移率为１４％，ＶＭ－２６组为１２．９％；ＶＰ－１６组的３～４级血液毒性发生率为２７．９１％，ＶＭ－２６组为５８．０６％。提示ＶＰ－１６与铂类联合的ＣＥＰ，ＥＰ方案和ＶＭ－２６＋ＤＤＰ，ＶＭ－２６＋Ｃａｒｂｏｐｌａｔｉｎ方案均可视为治疗小细胞肺癌的有效方案。Objective: To compare the clinical efficacy of VP 16(etoposide) with VM 26(teniposide) both plus platinum drugs combined with radiotherapy in the treatment of patients with small cell lung cancer(SCLC). Methods: Seventy four cases of SCLC were studied retrospectively. Forty three patients were treated with VP 16+DDP+CTX or VP 16+DDP, the other 31 patients were treated with VM 26+DDP or VM 26+Carboplatin. The treatment of both groups was combined with radiotherapy. Results: There was no significant difference between VP 16 and VM 26 groups in response rate, 2 year survival rate, and brain metastasis rate. But the blood toxicity was more serious in VM 26 group than in VP 16 group; 3～4 stage toxicity rate was 58.06% versus 27.91%. Conclusion: The results indicate that both VP 16 and VM 26 combined with platinum drugs were effective chemotherapy protocols. The authors suggest choosing VP 16 protocols as the first choice for previously untreated SCLC patients.

关 键 词：肺肿瘤 小细胞癌 放射疗法 VP-16 VM-26 

分 类 号：R734.205[医药卫生—肿瘤]